Cartesian Therapeutics Inc expected to post a loss of 88 cents a share - Earnings Preview

Cartesian Therapeutics

30/04/2024 14:55

* Cartesian Therapeutics Inc  RNAC.OQ   RNAC.O  is expected
to show a fall in quarterly revenue when it reports  results on
May 2 (estimated) for the period ending January 1 0001
    * The Watertown Massachusetts-based  company is expected to
report
a 78.9% decrease in revenue to $1.25 million from $5.94 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Cartesian Therapeutics
Inc is
for a loss of 88 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cartesian
Therapeutics Inc is $42.00​, above​ its last closing price
of $22.00. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023              -1.05      -2.10     Missed  -100
 Jan. 1 2023               -1.75      -1.80     Missed  -2.9
 Jun. 30 2023              -2.40      -2.10     Beat    12.5​
 Mar. 31 2023  -2.62       -2.61      -4.20     Missed  -60.7
 ​​Jan.                               1.20              154.9
 1 0001                                                 
 Jan. 1 0001                          -1.50             -775.7
                                                        ​
 Jan. 1 0001   -1.83       -2.31      1.80      Beat    177.8
 Jan. 1 0001   -2.94       -3.25      6.90      Beat    312.3
 This summary was machine generated April 30 at 13:54 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)